Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Chlebowski

Showing results (261-270 of 379) with videos related to

Pageof 38
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 2, 2009
A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancerGeoffrey C Kabat, Mimi Kim, Rowan T Chlebowski, et al.
International Journal of Cancer|July 10, 2009
Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancerGeoffrey C Kabat, Mimi Kim, Bette J Caan, et al.
Breast Cancer Research and Treatment|November 3, 2016
Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer riskMara A Schonberg, Vicky W Li, A Heather Eliassen, et al.
Journal of the National Cancer Institute|September 7, 2023
Validating a model for predicting breast cancer and nonbreast cancer death in women aged 55 years and olderEmily A Wolfson, Mara A Schonberg, A Heather Eliassen, et al.
JAMA|March 6, 2008
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestinGerardo Heiss, Robert Wallace, Garnet L Anderson, et al.
JAMA Network Open|July 1, 2020
Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast CancersVeronica L Irvin, Zhenzhen Zhang, Michael S Simon, et al.
JAMA|June 26, 2003
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized TrialRowan T Chlebowski, Susan L Hendrix, Robert D Langer, et al.
American Journal of Epidemiology|April 22, 2020
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy TrialsRoss L Prentice, Aaron K Aragaki, Rowan T Chlebowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2008
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trialCheryl Ritenbaugh, Janet L Stanford, LieLing Wu, et al.
Cancer Causes & Control : CCC|October 12, 2012
Recreational physical activity, body mass index, and survival in women with colorectal cancerJosephina G Kuiper, Amanda I Phipps, Marian L Neuhouser, et al.
Pageof 38

Showing results (261-270 of 379) with videos related to

Sort By:
Pageof 38
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 2, 2009
A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancerGeoffrey C Kabat, Mimi Kim, Rowan T Chlebowski, et al.
International Journal of Cancer|July 10, 2009
Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancerGeoffrey C Kabat, Mimi Kim, Bette J Caan, et al.
Breast Cancer Research and Treatment|November 3, 2016
Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer riskMara A Schonberg, Vicky W Li, A Heather Eliassen, et al.
Journal of the National Cancer Institute|September 7, 2023
Validating a model for predicting breast cancer and nonbreast cancer death in women aged 55 years and olderEmily A Wolfson, Mara A Schonberg, A Heather Eliassen, et al.
JAMA|March 6, 2008
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestinGerardo Heiss, Robert Wallace, Garnet L Anderson, et al.
JAMA Network Open|July 1, 2020
Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast CancersVeronica L Irvin, Zhenzhen Zhang, Michael S Simon, et al.
JAMA|June 26, 2003
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized TrialRowan T Chlebowski, Susan L Hendrix, Robert D Langer, et al.
American Journal of Epidemiology|April 22, 2020
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy TrialsRoss L Prentice, Aaron K Aragaki, Rowan T Chlebowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2008
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trialCheryl Ritenbaugh, Janet L Stanford, LieLing Wu, et al.
Cancer Causes & Control : CCC|October 12, 2012
Recreational physical activity, body mass index, and survival in women with colorectal cancerJosephina G Kuiper, Amanda I Phipps, Marian L Neuhouser, et al.
Pageof 38